Commercialization of the Xalkori Pediatric Multiparticulate Product Using Quality-by-Design Principles

A pediatric dosage form for crizotinib (Xalkori) was commercialized using quality-by-design principles in a material-sparing fashion. The dosage form consists of spherical multiparticulates (microspheres or pellets) that are coated and encapsulated in capsules for opening. The crizotinib (Xalkori)-c...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jeremy Bartlett, Natalie Culver, Xiang Zhang, Brett Waybrant, Hannah Sullivan, Logan Howell
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2024-08-01
Edice:	Pharmaceutics
Témata:	pediatrics multiparticulates microspheres dose flexibility uniformity commercialization
On-line přístup:	https://www.mdpi.com/1999-4923/16/8/1027
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!